AMRI renews 10-year $39.5m drug discovery contract

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/shironosov)
(Image: Getty/shironosov)
AMRI will provide various services supporting drug discovery programs in neurotherapeutics as part of a 10-year contract worth up to $39.5m.

The contract research, development, and manufacturing organization (CDMO) today announced its renewed contract with the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN). AMRI was originally awarded the contract in 2011.

As part of the renewal, AMRI will provide BPN with medicinal chemistry and absorption, distribution, metabolism, and excretion (ADME) services.

Chris Conway, AMRI’s senior vice president and head of drug discovery, chemical development and analytical services, told us the company is dedicated to advancing BPN's mission and "will continue to commit resources to support the growing needs of the companies involved with advancing drug discovery programs in neurotherapeutics.”

Services include exploratory chemistry, hit-to-lead and lead optimization efforts, including structure-activity-relationship (SAR) analysis and design, synthesis, in vitro ADMET studies, and computer-aided drug discovery, according to the company.

Additionally, as part of the contract, the National Institute of Neurological Disorders and Stroke (NINDS) will gain access to AMRI’s Buffalo, NY-based drug discovery center of excellence, which opened in December 2015​.

AMRI has three other contracts with the NIH and is a dedicated center for the National Cancer Institute’s (NCI) Chemical Biology Consortium (CBC).

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars